for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Strides Pharma Science Ltd

SRID.NS

Latest Trade

489.15INR

Change

-2.10(-0.43%)

Volume

743,890

Today's Range

487.85

 - 

497.10

52 Week Range

471.20

 - 

999.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
491.25
Open
492.00
Volume
743,890
3M AVG Volume
17.33
Today's High
497.10
Today's Low
487.85
52 Week High
999.00
52 Week Low
471.20
Shares Out (MIL)
89.78
Market Cap (MIL)
44,105.76
Forward P/E
-23.96
Dividend (Yield %)
0.51

Next Event

Q3 2022 Strides Pharma Science Ltd Earnings Release

Latest Developments

More

Strides Pharma Says Expected To Commercially Launch Sputnik Vaccine Within Q3FY22

India's Strides Pharma Science Reports Sept-Quarter Consol Loss Versus Profit Year Ago

Strides Pharma Science Reports June-Quarter Consol Net Loss Vs Yr Ago Profit

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Strides Pharma Science Ltd

Strides Pharma Science Ltd, formerly Strides Shasun Limited, is a vertically integrated global pharmaceutical company. The Company is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations, as well as biotech. Its business segments include Pharmaceutical and Biotech businesses. Its geographical segments are Africa, Australasia, North America and Europe, South and Central America, India and Others. The Company focuses on developing complex pharmaceutical products across therapeutic segments. The Company's products include general tablets, hard gelatin capsules, soft gelatin capsules, sachets, dry powders, dry syrups, potent drugs, semi solids, ointments and creams. It is also involved in supplying generics to hospitals approved by the National Health Service (NHS) and over-the-counter (OTC) products through retail outlets. It operates approximately 10 facilities, which are diversified across Asia, Africa and Europe.

Industry

Biotechnology & Drugs

Contact Info

Strides House

Bannerghatta Road, Bilekahalli

560076

India

+91.80.67840000

http://www.strides.com/

Executive Leadership

Deepak Vaidya

Non-Executive Chairman of the Board

R. Ananthanarayanan

Chief Executive Officer, Managing Director

Badree Komandur

Chief Financial Officer, Executive Director

Subroto Banerjee

President - Brands, India

Manjula Ramamurthy

Compliance Officer, Company Secretary

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

30.1K

2020

27.5K

2021

33.2K

2022(E)

32.0K
EPS (INR)

2019

6.280

2020

13.750

2021

25.090

2022(E)

-20.412
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.40
Price To Book (MRQ)
1.83
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
114.80
LT Debt To Equity (MRQ)
46.53
Return on Investment (TTM)
-7.69
Return on Equity (TTM)
-4.41

Latest News

Latest News

BRIEF-Strides Pharma Gets US FDA Approval For Triamcinolone Acetonide Ointment

* RECEIVES USFDA APPROVAL FOR TRIAMCINOLONE ACETONIDE OINTMENT Source text for Eikon: Further company coverage:

Strides Pharma to conduct trials in India for potential COVID-19 drug

Indian pharmaceutical company Strides Pharma Science Ltd on Thursday received regulatory approval to start clinical trials of antiviral drug favipiravir, which has been touted as a potential treatment for COVID-19.

Strides Pharma to conduct trials in India for potential COVID-19 drug

Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has obtained regulatory approval to conduct clinical trials of antiviral drug favipiravir, a potential treatment for COVID-19.

BRIEF-India's Strides Pharma Science Posts March Quarter Consol Net Loss

* MARCH QUARTER CONSOL NET LOSS 2.07 BILLION RUPEES VERSUS PROFIT OF 595 MILLION RUPEES LAST YEAR

BRIEF-Strides Pharma Science Develops, Commences Export Of Favipiravir Antiviral Tablets

* STRIDES DEVELOPS AND COMMENCES EXPORT OF FAVIPIRAVIR ANTIVIRAL TABLETS

BRIEF-Strides Pharma Science Says Unit Gets USFDA Approval For Flucytosine Capsules

* STRIDES RECEIVES USFDA APPROVAL FOR FLUCYTOSINE CAPSULES Source text for Eikon: Further company coverage:

BRIEF-Strides Pharma Science Updates As U.S. FDA Requests Withdrawal Of Ranitidine Products From U.S. Market

* UPDATES AS U.S. FDA REQUESTS ALL MANUFACTURERS TO WITHDRAW RANITIDINE PRODUCTS FROM U.S. MARKET

BRIEF-Strides Pharma Science Successfully Completes U.S FDA Inspection At Bangalore Unit

* SUCCESSFULLY COMPLETED US FDA INSPECTION CONDUCTED IN JANUARY 2020 AT FACILITY IN BANGALORE

BRIEF-FDA Confirms Closure Of Inspections At Strides Pharma Science's Bangalore Facility

* RECEIVES EIR FROM USFDA ON CONTINUED GMP STATUS FOR FLAGSHIP FACILITY IN BANGALORE Source text for Eikon: Further company coverage:

BRIEF-India's Strides Pharma Science To Acquire 18 ANDAs From Pharmaceutics International

* STRIDES PHARMA SCIENCE LTD - TO ACQUIRE 18 ANDAS FROM PHARMACEUTICS INTERNATIONAL INC

India's Strides Pharma halts U.S. sales of heartburn drug

India's Strides Pharma Science Ltd said on Friday it has halted sales of its heartburn drug Ranitidine in the U.S. market as it conducts tests to identify possible cancer-causing impurities in the tablets.

India's Strides tried to shred quality-control documents: FDA

The U.S. Food and Drug Administration (FDA) has raised doubts about Strides Pharma Sciences Ltd's quality-control practices after finding adulteration and evidence of "uncontrolled shredding of documents" at one of its plants.

US FDA finds "significant violations" at India's Strides plant

The U.S. Food and Drug Administration (FDA) said it found adulteration and "significant violations" of current good manufacturing practice (CGMP) regulations at Strides Pharma Sciences Ltd's plant in Puducherry in south India.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up